OOIR: Observatory of International Research

Papers

(The median citation count of Current Hematologic Malignancy Reports is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Monoclonal Gammopathy-Associated Neuropathy	137
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions	33
Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations	26
Targeting RUNX1 Germline Variants: Agents Under Investigation	21
Telomere Biology Disorder: A Focus on Gastrointestinal and Hepatic Manifestations	20
Management of Chronic Myeloid Leukemia in Children and Young Adults	18
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications	18
Splicing Factor Mutations in Chronic Myelomonocytic Leukemia: Biological Consequences and Therapeutic Implications	17
Contemporary Updates in the Prevention and Treatment of Graft-Versus-Host Disease	17
Value in Myeloma Care: Myth or Reality	17
Correction to: Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	17
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer	16
Targeting Apoptosis in ALL	15
Allogeneic Transplant for CMML	14
Transplantation and Cellular Therapy for Older Adults—The MSK Approach	14
Prognostic and Predictive Models in Myelofibrosis	13
How Do We Manage Chronic Lymphocytic Leukemia in India	13
Multidisciplinary Approach to Older Adults with Hematologic Malignancies—a Paradigm Shift	13
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders	13
Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies	11
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications	11
Multiple Myeloma: Current Clinical Landscape and Compounding Costs	11
Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults	10
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies	10
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia	10

Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia	9
Impact of Germline DNA Repair Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Development	8
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma	8
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders	8
Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders	8
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies	8
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia	8
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes	7
Impact of Epigenetic Mutations in Chronic Myelomonocytic Leukemia	7
CAR-T Cell Therapy: the Efficacy and Toxicity Balance	7
Prevalence and Determinants of Return to Work as a Patient-Centered Outcome in Survivors of Hematopoietic Cell Transplantation	7
Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera	6
Pediatric Germline Predisposition to Myeloid Neoplasms	6
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	6
Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms	6
Maintenance Therapy Post-Stem Cell Transplantation for Patients with T-Cell Lymphomas	6
JAK Inhibitors for Myelofibrosis: Strengths and Limitations	6
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma	6
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia	6
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms	5
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals	5
Defining Higher-Risk Chronic Myeloid Leukemia: Risk Scores, Genomic Landscape, and Prognostication	5
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms	5
Novel Therapies in Myelofibrosis: Beyond JAK Inhibitors	4
Germline Abnormalities in DNA Methylation and Histone Modification and Associated Cancer Risk	4
Measurable Residual Disease Monitoring in Lymphoma	4
Management of CNS Disease in Pediatric Acute Lymphoblastic Leukemia	4
Real-world Management of CML: Outcomes and Treatment Patterns	4
Plasmacytoid Dendritic Cell-Expansion in Acute Myeloid Leukemia (pDC‑AML): a Review of Clinicopathologic Features, Genetics, and Outcomes	4
The Evolving Therapeutic Landscape of Richter Transformation	4
Managing Survivorship after Hematopoietic Cell Transplantation	3
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases	3
Use of Patient-Reported Outcome Measures in Clinical Studies of Chronic Myeloid Leukemia: A Scoping Literature Review	3
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors	3
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities	3
Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities	3
The Role of Inflammation in CMML Pathobiology and Progression	3
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition	3
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies	3